Drugs / EG-MCV4
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07204457 | Oct 2025 → Sep 2026 expected | meningococcal infection | EyeGene Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-MCV4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07204457 ↗ |
| Modality | Vaccine | “conjugate vaccine” NCT07204457 ↗ |
| Route | Intramuscular | “single intramuscular dose on Day 0” NCT07204457 ↗ |